NCT05210517View on ClinicalTrials.gov

SGLT2 Inhibition: Uric Acid Excretion Study

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

June 8, 2021

Study Completion Date

September 1, 2021

Conditions
Type 2 Diabetes
Interventions
DRUG

Empagliflozin 25 MG

25 once daily one week treatment

DRUG

Benzbromaron

100 mg once daily 1 one week treatment

DRUG

Empagliflozin 25 MG + benzbromarone 100 mg

combined treatment once daily for one week

Trial Locations (1)

1081HV

VU University Medical Center, Amsterdam

All Listed Sponsors
lead

Amsterdam UMC, location VUmc

OTHER

NCT05210517 - SGLT2 Inhibition: Uric Acid Excretion Study | Biotech Hunter | Biotech Hunter